EC Number   |
Application |
Reference |
|---|
    6.1.1.10 | drug development |
parasite MetRS is an attractive drug target due to its essential role in protein synthesis and cell survival. Comparative sequence analysis discloses differences between the trypanosome and mammalian methionyl-tRNA synthetases |
713772 |
| 6.1.1.10 | medicine |
methionyl-tRNA synthetase overexpression is associated with poor clinical outcomes in non-small cell lung cancer |
744596 |
| 6.1.1.10 | medicine |
REP3123 is a fully synthetic methionyl-tRNA synthase inhibitor in pre-clinical development as a novel agent to treat Clostridium difficile infection, CDI |
704224 |
| 6.1.1.10 | medicine |
REP3123 represents a promising narrow spectrum, new mode-of-action agent with an excellent microbiological profile that warrants its further evaluation as a novel drug |
704223 |
| 6.1.1.10 | medicine |
REP3123 represents a promising narrow spectrum, new mode-of-action agent with an excellent microbiological profile that warrants its further evaluation as a novel drug to combat Clostridium difficile infections |
704223 |
| 6.1.1.10 | medicine |
REP8839 is a selective inhibitor of methionyl-tRNA synthetase with antibacterial activity against a variety of gram-positive organisms |
701744 |
| 6.1.1.10 | pharmacology |
the enzyme is an important antibiotic target |
671376 |
